Inhaled Nitric Oxide for Pulmonary Hypertension in Extremely Premature Infants: A Critical Reevaluation of Recent Clinical Trial Findings
The treatment of pulmonary hypertension (PH) in extremely premature infants remains a contentious and evolving area in neonatology. A recently published single-center double-blinded randomized controlled trial (RCT) sought to evaluate the efficacy of inhaled nitric oxide (iNO) administered in the early detection of echocardiographic PH, with the aim of reducing bronchopulmonary dysplasia (BPD) and mortality outcomes measured at 36 weeks postmenstrual age. Despite the promise that iNO has demonstrated in select patient populations, this novel trial was terminated early and concluded a lack of significant benefit for iNO use in this setting, particularly in premature infants presenting with early PH but absent hypoxic respiratory failure (HRF). However, the broader implications and precise interpretation of these findings demand nuanced consideration given several critical methodological limitations and the complexities inherent in neonatal pulmonary vascular physiology.
The persistence of controversy surrounding iNO in the neonatal intensive care of premature infants derives from contrasting clinical trial data and divergent professional guidelines. Historically, consensus statements from authoritative bodies such as the National Institutes of Health (NIH) and the American Academy of Pediatrics have generally recommended against iNO therapy in preterm infants, cautioning clinicians due to a lack of robust evidence supporting efficacy and concerns about safety. These guidelines predominantly reflect trials that judged PH severity and treatment response using indirect clinical parameters such as oxygenation index and respiratory distress scores, rather than direct, standardized echocardiographic evaluations of pulmonary arterial pressure (PAP) and pulmonary vascular resistance.
More recent clinical observations and registry data have suggested that iNO might be beneficial in carefully selected subsets of preterm infants with pulmonary arterial hypertension, especially when resistance-mediated PH is precisely diagnosed through comprehensive echocardiographic techniques, showcasing measurable reductions in pulmonary artery pressures and improvements in oxygenation during the transitional physiology period after birth. Prospective cohort studies have underscored this possibility, demonstrating notable responsiveness to iNO in infants as immature as 22 weeks gestation. Thus, while the recent RCT found no statistically significant differences in BPD or mortality outcomes, the discordance between real-world clinical experience and controlled trial data necessitates deeper analysis into the study design and population characteristics.
One major limitation of the trial is its reliance on echocardiographic criteria alone to evaluate PH severity and iNO treatment response, without integration of oxygenation parameters reflective of clinical status. Interestingly, infants enrolled in the trial were required to have a fractional inspired oxygen (FiO2) below 30%, a relatively low oxygen requirement inconsistent with typical clinical indications for initiating iNO. This low baseline FiO2 could have constrained the capacity to detect meaningful improvements in oxygenation following iNO administration, thus potentially underestimating the therapeutic effect. Furthermore, the trial excluded infants who had received iNO for HRF before enrollment—precisely those with more severe disease who might derive the most benefit from treatment. Such stringent inclusion criteria essentially limit generalizability and may mask the true impact of iNO in higher-risk populations characterized by severe PH.
Cardiovascular physiology during neonatal transition is complex and dynamic, and the trial’s approach to PH assessment did not reflect this known variability. Parameters such as patent ductus arteriosus (PDA) gradient, maximum tricuspid regurgitation velocity (TRVmax), and septal flattening were obtained to estimate PAP, yet the trial did not rigorously characterize different PH phenotypes—namely resistance-mediated, flow-mediated, or post-capillary PH. These distinctions are critical, because each phenotype involves distinct pathophysiology and differing responses to vasodilator therapy such as iNO. The assumption of a static PH phenotype over time ignored potential hemodynamic shifts during the neonatal course, including transitions from resistance-mediated to flow-mediated PH. This oversight could obscure understanding of iNO responsiveness and risks inadvertently prolonging treatment when weaning is clinically indicated, with potential adverse effects such as increased risk of intraventricular hemorrhage secondary to reperfusion injury or systemic hypoperfusion.
Critically, the therapeutic monitoring protocols within the trial did not employ multiparametric targeted neonatal echocardiography, which current consensus guidelines endorse to achieve precision in diagnosing PH subtypes and tailoring interventions. Incorporating comprehensive echocardiographic assessment combining qualitative and quantitative data, including function of both ventricles, loading conditions, shunt dynamics, and pulmonary arterial pressures, offers a nuanced understanding that could optimize iNO dosing, timing, and duration. This is paramount in premature infants, whose cardiopulmonary physiology can rapidly evolve.
The trial also highlighted the limited data defining the optimal dosing and weaning strategies for iNO in premature infants with resistance-mediated PH. This is a crucial knowledge gap, as iNO dose and exposure duration appear to modulate therapeutic outcomes. Some neonatal intensive care units have adopted protocols involving lower initial doses of iNO accompanied by meticulous monitoring of hemodynamic and respiratory parameters, allowing for personalized weaning schedules. This approach may mitigate adverse events and maximize benefit but was not explored or accounted for in the recent trial, potentially influencing the overall findings.
Another confounding variable insufficiently addressed in the study is the role of PDA physiology, which significantly influences pulmonary hemodynamics in premature infants. The study did not assess how ductal size, shunt directionality, and temporal changes affected PH evaluation and response to iNO. Ductal closure and left-to-right shunting alter pulmonary blood flow and pressure, complicating the attribution of changes in PAP solely to intrinsic pulmonary vascular tone. Overlooking these nuances risks misclassification of PH severity and therapeutic response, impairing both trial outcomes and clinical decision-making.
Given these considerations, the premature termination of the trial and its null findings regarding the utility of iNO in treating early PH in extremely premature infants with low oxygen needs should be interpreted with caution. The study’s design choices limit its applicability, failing to capture the spectrum and dynamism of pulmonary vascular disease in this fragile population. Consequently, the results do not justify wholesale abandonment of iNO therapy in neonates with echocardiographically confirmed PH, especially those demonstrating clinical signs of significant pulmonary vascular compromise.
Moving forward, future investigations must integrate comprehensive echocardiographic phenotyping with serial assessments to elucidate the complex interplay of pulmonary vascular resistance, cardiac function, and shunt physiology. Trials incorporating variable dosing regimens and stratification by PH subtype alongside rigorous safety monitoring can better define which subpopulations of premature infants stand to benefit most from iNO therapy. The precision medicine approach incorporating multiparametric echocardiographic tools and individualized treatment algorithms represents the frontier for optimizing outcomes in neonatal pulmonary hypertension.
In conclusion, this recent RCT contributes valuable data to the ongoing dialogue surrounding iNO use in extremely premature infants but is constrained by significant methodological limitations that temper its conclusions. Neonatologists must continue to employ a detailed, physiology-based approach when assessing pulmonary hypertension and considering iNO therapy rather than relying solely on simplified clinical trial outcomes. As the understanding of neonatal PH pathophysiology deepens and echocardiographic technology advances, tailored therapeutic interventions hold promise for improving both survival and long-term respiratory outcomes for the most vulnerable infants.
Subject of Research:
Efficacy of inhaled nitric oxide therapy in the treatment of pulmonary hypertension among extremely premature infants.
Article Title:
Does inhaled nitric oxide treatment of pulmonary hypertension in extremely premature infants improve patient outcomes?
Article References:
King, T.L., McNamara, P.J. & Bischoff, A.R. Does inhaled nitric oxide treatment of pulmonary hypertension in extremely premature infants improve patient outcomes?. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02666-1
Image Credits:
AI Generated
DOI:
09 April 2026
